Literature DB >> 15202527

AIDS-related non-Hodgkin's lymphoma: etiology, epidemiology, and impact of highly active antiretroviral therapy.

Richard F Little1.   

Abstract

Lymphoproliferative disorders (LPD) occur more frequently in the immunosuppressed host compared to those who are immunocompetent. The biological and clinical characteristics of a particular LPD are specific to the underlying immune defect, though there are clear similarities in the various tumor types that occur. Immunosuppression-related LPD are more frequently associated with gamma-herpesviruses suggesting that the immunologic environment influences tumorigenesis. Clinical outcomes may be optimized when appropriate treatment strategies are based on consideration of the underlying immunodeficiency and on the tumor biology. Consistent with this observation, in AIDS-related lymphomas (ARL), tumor biology, clinical presentations, and treatment outcomes are correlated with the CD4 cell count. This review will consider the role of immune deficiency in HIV disease on ARL pathogenesis and epidemiology, and the impact that highly active antiretroviral therapy has had in this disease.

Entities:  

Mesh:

Year:  2003        PMID: 15202527     DOI: 10.1080/10428190310001623748

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons.

Authors:  Chun Chao; Lanfang Xu; Donald I Abrams; William J Towner; Michael A Horberg; Wendy A Leyden; Michael J Silverberg
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

2.  Polymorphous lymphoproliferative disorder: a clinicopathological analysis.

Authors:  Naoto Nakamichi; Naoki Wada; Masaharu Kohara; Shirou Fukuhara; Haruo Sugiyama; Hiroyasu Ogawa; Masayuki Hino; Akihisa Kanamaru; Yuzuru Kanakura; Eiichi Morii; Katsuyuki Aozasa
Journal:  Virchows Arch       Date:  2010-01-29       Impact factor: 4.064

Review 3.  How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.

Authors:  Thomas S Uldrick; Richard F Little
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

4.  The global burden of cancer: priorities for prevention.

Authors:  Michael J Thun; John Oliver DeLancey; Melissa M Center; Ahmedin Jemal; Elizabeth M Ward
Journal:  Carcinogenesis       Date:  2009-11-24       Impact factor: 4.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.